Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Forte Biosciences, Inc. (TOCA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/04/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
Docs: "Letter of Mayer Hoffman McCann P.C. to the Securities and Exchange Commission"
08/01/2023 8-K Quarterly results
03/31/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"FORTE BIOSCIENCES, INC. ANNOUNCES FULL YEAR 2022 RESULTS AND PROVIDES BUSINESS UPDATE"
02/09/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amended and Restated Bylaws",
"Amended and Restated Bylaws"
01/12/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"MR. DAVID GRYSKA APPOINTED TO FORTE BIOSCIENCES BOARD OF DIRECTORS"
11/14/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"FORTE BIOSCIENCES, INC. ANNOUNCES THIRD QUARTER 2022 RESULTS AND PROVIDES BUSINESS UPDATE",
"DR. SCOTT BRUN, M.D. APPOINTEED TO FORTE BIOSCIENCES BOARD OF DIRECTORS"
08/15/2022 8-K Quarterly results
08/12/2022 8-K Quarterly results
07/12/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/18/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/02/2022 8-K Quarterly results
09/02/2021 8-K Quarterly results
06/04/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/10/2021 8-K Quarterly results
03/24/2021 8-K Quarterly results
11/10/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Forte Biosciences, Inc. Investor Presentation"
11/09/2020 8-K Quarterly results
Docs: "FORTE BIOSCIENCES, INC. ANNOUNCES THIRD QUARTER 2020 RESULTS AND PROVIDES GENERAL BUSINESS UPDATE"
10/29/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement",
"Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation"
09/09/2020 8-K Quarterly results
09/04/2020 8-K Quarterly results
08/10/2020 8-K Quarterly results
07/21/2020 8-K Quarterly results
06/26/2020 8-K Quarterly results
06/15/2020 8-K Resignation/termination of a director
Docs: "Exhibit",
"Certificate of Amendment related to the Reverse Stock Split and Name Change, filed June 15, 2020",
"Agreement for Termination of Lease and Voluntary Surrender of Premises, by and between Tocagen, Inc. and ARE-SD Region No. 61, LLC",
"FORTE BIOSCIENCES, INC. ANNOUNCES CLOSING OF MERGER WITH TOCAGEN To Commence Trading on Nasdaq Capital Market on June 16, 2020 Under Ticker Symbol “FBRX”"
06/12/2020 8-K Submission of Matters to a Vote of Security Holders
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 June 12, 2020 Date of Report Tocagen Inc. Delaware 001-38052 26-1243872 4445 Eastgate Mall, Suite 200 San Diego, CA 92121 Registrant's telephone number, including area code: 412-8400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communication..."
06/08/2020 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 June 8, 2020 Date of Report Tocagen Inc. Delaware 001-38052 26-1243872 4445 Eastgate Mall, Suite 200 San Diego, California 92121 Registrant's telephone number, including area code: 412-8400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement commun..."
05/01/2020 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
04/23/2020 8-K Quarterly results
Docs: "Press Release"
04/15/2020 8-K Termination of a Material Definitive Agreement
02/27/2020 8-K Quarterly results
02/21/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy